Immune reconstitution in HIV-1-infected patients

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1138-1145

  Imami, Nesrina ^a   Hardy, Gareth ^a   Pires, Antonio ^a   Burton, Catherine ^a   Pido Lopez, Jeffrey ^a   Mela, Christopher ^a   Gotch, Frances ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CD4+ T helper cell responses; CD8+ cytotoxic T cells; HIV 1 infection; Immunotherapy; Therapeutic immunization

Indexed keywords

ADENOVIRUS VACCINE; ALBANY VACCINE 1452; ANTIGEN; ANTIRETROVIRUS AGENT; CANARYPOX VIRUS VACCINE; CYTOKINE; DERMAVIR; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN P17 P24 VIRUS LIKE PARTICLE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; NUCLEOSIDE ANALOG; THYMOSIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS VACCINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; EFFECTOR CELL; ERADICATION THERAPY; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PROBABILITY; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; STAGING; TREATMENT OUTCOME; VIRUS INHIBITION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HORMONES; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOTHERAPY;

EID: 0036707271     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 338(13):853-860.
2. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med (1999) 341(25):1865-1873.
3. Pierson T, Mcarthur J, Siliciano RF: Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 18:665-708. A review describing life-long persistence of latent reservoirs of HIV-1, even in patients receiving effective antiretroviral therapy.
4. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune respone of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis (1996) 173(2):321-329.
5. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 277(5322):112-116.
6. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, Metcalf JA, Walker RE, Falloon J, Baseler M, Feuerstein I et al: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3(5):533-540.
7. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 351(9117):1682-1686.
8. Wilson JD, Imami N, Watkins A, Gill J, Hay P, Gazzard B, Westby M, Gotch FM: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis (2000) 182(3):792-798. This paper gave the initial indication that defects in the ability of CD4+ T-cells to proliferate and produce IL-2, rather than loss of HIV-1 specificity, is associated with disease progression.
9. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV et al: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 192(1):63-75. This paper revealed that defects in the cytolytic capacity of CD8+ T-cells, but not the ability to produce antiviral cytokines, is associated with disease progression.
10. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, Ehler L, Prussin C, Stevens R, Lambert L, Altman J, et al: Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol (2000) 165(2):1082-1092. This paper revealed that defects in the cytolytic capacity of CD8+ T-cells but not the ability to produce antiviral cytokines, is associated with disease progression.
11. Kalams SA, Walker BD: The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998) 188(12):2199-2204.
12. Gotch F, Hardy G, Imami N: Therapeutic vaccines in HIV-1 infection. Immunol Rev (1999) 170:173-182.
13. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 278(5342):1447-1450. These studies revealed significant negative correlation between plasma viremia and virus-specific CD4+ T-helper cells. Furthermore, early institution of potent antiretroviral therapy led to persistent, strong HIV-1-specific T-helper cell responses, analogous to those seen in long-term non-progressors.
14. Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD: Anti-HIV cellular immunity: Recent advances towards vaccine design. AIDS (1999) 13(Suppl A):S121-136.
15. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, Walker BD: Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 73(8):6715-6720.
16. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393(6684):474-478.
17. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 68(7):4650-4655.
18. Klein MR, Van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 181(4):1365-1372.
19. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 337(18):1267-1274.
20. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z et al: HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 417(6884):95-98. This paper showed that HIV-1-specific CD4 T-cells are preferentially infected by HIV-1 in vivo, and provided an explanation for the loss of HIV-1-specific CD4 T-cell responses and subsequent loss of control of viral replication.
21. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP: The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Ann Rev Immunol (2000) 18:529-560.
22. Haase AT: Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol (1997) 17:625-656.
23. Knight SC, Patterson S: Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu Rev Immunol (1997) 15:593-615.
24. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R et al: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410(6824):106-111. These studies suggested a selective defect in HIV-1 infection in the maturation of fully responsive CD8+ effector cells.
25. Van Baarle D, Kostense S, Hovenkamp E, Knol GJ, Van Oers MHJ, Miedema F: Lack of differentiation of virus-specific CD8+ T cells into CD27-effector cells is associated with progression to disease. Eighth Conference on Retrovirus and Opportunistic Infections (2001):Abs 275.
26. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 296(5572):1439-1443. The authors provide evidence of a fundamental role for HLA-restricted immune responses in driving and shaping variatiosn in HIV-1 proteins and the evolution of HIV-1 itself.
27. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J et al: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 278(5341):1295-1300.
28. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC et al: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 5(5):512-517. This paper lists measurements of the decay rate of the latent reservoir of HIV-1 in treated individuals. The half-life of the latent reservoir was calculated to be 43.9 months.
29. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 6(1):82-85.
30. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407(6803):523-526.
31. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, Sontag G, Sewell AK, Phillips RE: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ lymphocytes. Proc Natl Acad Sci USA (2000) 97(7):3382-3387.
32. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE et al: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 193(2):169-180. Protective HIV-1-specific CD4 T-cell responses are lost within a short period following seroconversion.
33. Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J: Control of SIV rebound through structured treatment interruptions during early infection. Science (2000) 290(5496):1591-1593. Early institution of potent antiretroviral drug therapy leads to preservation of strong HIV-1-specific T-cell responses and these were maintained even after antiretroviral therapy was stopped. Furthermore, this was associated with viral replication control.
34. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, Lori F: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med (1999) 340(21):1683-1684.
35. Imami N, Hardy G, Burton C, Pires A, Pido-Lopez J, Moss R, Gazzard B, Gotch F: Immune responses and reconstitution in HIV-1 infected individuals: Impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunol Lett (2001) 79(1-2):63-76.
36. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B: Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol (2001) 75(1):234-241.
37. Tumer JL, Trauger RJ, Daigle AE, Carlo DJ: HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: Results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS (1994) 8(10):1429-1435.
38. Levine AM, Groschen S, Allen J, Munson KM, Carlo DJ, Daigle AE, Ferre F, Jensen FC, Richieri SP, Trauger RJ, Parker JW et al: Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: Long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 11(4):351-364.
39. Moss RB, Trauger RJ, Giermakowska WK, Turner JL, Wallace MR, Jensen FC, Richieri SP, Ferre F, Daigle AE, Duffy C, Theofan G, Carlo DJ: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 14(4):343-350.
40. Churdboonchart V, Sakondhavat C, Kulpradist S, Na Ayudthya BI, Chandeying V, Rugpao S, Bronshuyar C, Sukeepaisarcnharoen W, Sirawarapom W, Carlo DJ, Moss R: A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of > 300. Clin Diagn Lab Immunol (2000) 7(5):728-733.
41. Moss RB, Wallace MR, Giemakowska WK, Webb E, Savary J, Chamberlin-Brandt C, Theofan G, Musil R, Richieri SP, Jensen FC, Carlo DJ: Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis (1999) 180(3):641-648.
42. Moss RB, Giermakowska WK, Wallace MR, Jensen FC, Maigetter RZ, Carlo DJ: Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen. Clin Exp Immunol (2001) 124(2):248-254.
43. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S: Evaluation of HIV-1 immunogen, an immunologic modifier administered to patients infected with HIV having 300 to 549 × 10(6)/C CD4 cell counts: A randomized controlled trial. J AM Med Assoc (2000) 284(17):2193-2202.
44. Fernández-Cruz E, Muñoz-Fernandez MA, Navarro J, Clotet B, Gonzalez-Lahoz J, Moreno S, Peña JM Randomized control phase I trial evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection having 300 to 700 cells/μl CD4 cell counts: Data from a recently unblinded study. First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001).
45. Turner JL, Kostman JR, Aquino A, Wright D, Szabo S, Bidwell R, Goodgame J, Daigle A, Kelley E, Jensen F, Duffy C, et al: The effects of an HIV-1 immunogen (Renune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med (2001) 2(2):68-77.
46. Moss RB, Wallace MR, Steigbigel RT, Morrison SA, Giermakowska WK, Nardo CJ, Diveley JP, Carlo DJ: Predictors of HIV-specific lymphocyte proliferation immune responses induced by therapeutic vaccination. Clin Exp Immunol (2002) 128(2):359-364.
47. Moss RB, Diveley J, Jensen FC, Gouveia E, Carlo DJ: Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioateguanine dinucleotide immunostimulatory sequences of DNA. J Hum Virol (2001) 4(1):39-43.
48. Gotch F, Hardy G, Imami N, Sullivan A, Nelson M, Burton C, Pido-Lopez J, Pires A, Moss R, Gazzard B: The effects of immunotherapy with cytokines and/or vaccines in HAART treated patients. 14th International AIDS Conference (2002): ThOrA1483.
49. Smith DE, Boag F, Colebunders R: Therapeutic vaccination (p24 VLP) of patients with advanced HIV-1 infection does not alter CD4 decline. AIDS (1996) 10(Suppl 2):S14.
50. Veenstra J, Williams IG, Colebunders R, Dorrell L, Tchamouroff SE, Patou G, Lange JM, Weller IV, Goeman J, Uthayakumar S, Gow IR et al: Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis (1996) 174(4):862-866.
51. Peters BS, Cheingsong-Popov R, Callow D, Foxall R, Patou G, Hodgkin K, Weber JN: A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect (1997) 35(3):231-235.
52. Klein MR, Veenstra J, Holwerda AM, Roos MT, Gow I, Patou G, Coutinho RA, De Wolf F, Miedema F: Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses (1997) 13(5):393-399.
53. Kelleher AD, Roggensack M, Jaramillo AB, Smith DE, Walker A, Gow I, McMurchie M, Harris J, Patou G, Cooper DA: Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators. AIDS (1998) 12(2):175-182.
54. Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, Boag F, Hales G, Adams S, Patou G, Cooper DA: Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART ere does not alter CD4 cells decline. HIV Med (2001) 2(4):272-275.
55. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A et al: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 324(24):1677-1684.
56. Biselli R, Loomis LD, Del Bono V, Burke DS, Redfield RR, Birx DL: Immunization of HIV-infected patients with rgp160: Modulation of anti-rgp120 antibody spectrotype. J Acquir Immune Defi Syndr (1994) 7(10):1016-1024.
57. Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC: Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses. J Acquir Defic Syndr Hum Retrovirol (1997) 15(4):269-274.
58. Wahren B, Bratt G, Persson C, Leven B, Hinkula J, Gilijam G, Nordlund S, Eriksson L, Volvovitz F, Broiden PA et al: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr (1994) 7(3):220-229.
59. Sitz KV, Ratto-Kim S, Hodgkins AS, Robb ML, Birx DL: Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. J Infect Dis (1999) 179(4):817-824.
60. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T et al: Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis (2000) 181(3):881-889.
61. Orentas RJ, Hildreth JE, Obah E, Polydefkis M, Smith GE, Clements ML, Siliciano RF: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science (1990) 248(4960):1234-1237.
62. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL et al: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 114(2):119-127.
63. Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, Fong IW, Schlech W, Djurdjev O, Freedman J, Thomas R et al: Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res Hum Retroviruses (1998) 14(6):483-490.
64. Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, Tamburrini E, Prozzo A, Seeber AC, Vella S, Ortona L, Aiuti F: Phase II controlld trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS (1998) 12(5):473-480.
65. Leandersson AC, Bratt G, Hinkula J, Gilljam G, Cochaux P, Samson M, Sandstrom E, Wahren B: Induction of specific T-cell responses in HIV infection. AIDS (1998) 12(2):157-166.
66. Sandstrom E, Wahren B: Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 353(9166):1735-1742.
67. Jin X, Ramanathan M Jr, Barsoum S, Deschenes GR, Ba L, Binley J, Schiller D, Bauer DE, Chen DC, Hurley A, Gebuhrer L et al: Safety and immunogenicity of ALVAC cCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol (2002) 76(5):2206-2216.
68. Goh LE, Perrin L, Hoen B, Cooper D, Phillips A, Janossy G, Sonnenborg A, Tsoukas C, Lampe F, Kinloch S: Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST study. HIV Clin Trials (2001) 2(5):438-444.
69. Emini E, for the HIV-1 Vaccine Research Team: A potential HIV-1 vaccine using a replication-defective adenoviral vaccine vector. Ninth Conference on Retroviruses and Opportunistic Infections (2002): Abs L5.
70. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR et al: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis (1998) 178(1):92-100.
71. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 351(9112):1320-1325.
72. Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman DM, Weinhold KJ, Sandstrom E, Wahren B: Immune responses in asymptomatic HIV-1-infected after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol (1999) 163(4):2330-2338.
73. Hanke T, McMichael A: Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett (1999) 66(1-3):177-181.
74. Wu S, Pascual DW, Lewis GK, Hone DM: Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res Hum Retroviruses (1997) 13(14):1187-1194.
75. Lisziewicz J, Xu J, Trocio J, Whitman L, Markham P, Arya S, Behr J-P, Lori F: A novel topical DNA vaccine (DermaVir) for the induction of T-cell immunity. Ninth Conference on Retroviruses and Opportunistic Infections (2002): Abs 286-W.
76. Mitsuyasu RT: The potential role of interleukin-2 in HIV. AIDS (2001) 15(Suppl 2):S22-7.
77. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP et al: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med (1995) 332(9):567-575.
78. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 335(18):1350-1356.
79. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H et al: A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis (1999) 179(4):849-858.
80. Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boumsell L, Gomard E, Rabian C et al: Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial. ANRS 048 study group. Lancet (1999) 353(9168):1923-1929.
81. Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM et al: Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 284(2):183-189.
82. Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, Smolskis M, Saravolatz LD, Lane HC, Fyfe GA, Curtin PT: Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis (2000) 182(2):428-434.
83. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, Borchard C, Muller K, Beckmann A, Eppner MT, Berger A, Fiedler M: Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS (1998) 12(17):F225-F234.
84. Caggiari L, Zanussi S, Bortolin MT, D'andrea M, Nasti G, Simonelli C, Tirelli U, De Paoli P: Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients. Clin Exp Immunol (2000) 120:101-106.
85. Pandolfi F, Pierdominici M, Marziali M, Livia Bernardi M, Antonelli G, Galati V, D'Offizi G, Aiuti F: Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clin Immunol (2000) 94(3):153-159.
86. Amendola A, Poccia F, Martini F, Gioia C, Galati V, Pierdominici M, Marziali M, Pandolfi F, Colizzi V, Piacentini M, Girardi E, D'offiz G: Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group. Clin Exp Immunol (2000) 120(2):324-332.
87. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, Vaccher E, Nasti G, Politi D, Barzan L, Tirelli U, De Paoli P: Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol (1999) 116(3):486-492.
88. Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P et al: Low-dose daily subcutaneos interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial. HIV Clin Trials (2000) 1(3):1-15.
89. 3. J Infect Dis (2000) 181(5):1614-1621.
90. Sullivan AK, Imami N, Hardy G, Burton C, Pires A, Nelson MR, Moss R, Gotch FM, Gazzard BG: Viral blips and HIV-1-specific helper T cell responses in patients on HAART receiving IL-2 therapy with or without a therapeutic vaccine. First AS Conference on HIV Pathogenesis and Treatment (2001): Abs 660.
91. Chun TW, Engel D, Mizell SB, Hallahan CW, Fichette M, Park S, Davey RT Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM et al: Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 5(6):651-655.
92. Amo A, Ruiz L, Juan M, Jou A, Balague M, Zayat MK, Marfil S, Martinez-Picado J, Martinez MA, Romeu J, Pujol-Borrell R et al: Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ 250/μl CD4 T cells and undetectable plasma virus load. J Infect Dis (1999) 180(1):56-60.
93. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K et al: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290(5491):486-492.
94. Angel JB: Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. AIDS Read (2001) 11(4):209-221.
95. Deresinski SC: Granulocyte-macrophage colony-stimulating factor: Potential therapeutic, immunological and antiretroviral effects in HIV infection. AIDS (1999) 13(6):633-643.
96. Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, Gilbert MJ, Deresinki S: Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS (2000) 14(4):387-395.
97. Brites C, Gilbert MJ, Pedral-Sampaio D, Bahia F, Pedroso C, Alcantara AP, Sasaki MD, Matos J, Renjifo B, Essex M, Whitmore JB et al: A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. J Infect Dis (2000) 182(5):1531-1535.
98. Kedzierska K, Mak J, Mijch A, Cooke I, Rainbird M, Roberts S, Paukovics G, Jolley D, Lopez A, Crowe SM: Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J Infect Dis (2000) 181(1):390-394.
99. Skowron G, Stein D, Drusano G, Melbourne K, Bilello J, Mikolich D, Rana K, Agosti JM, Mongilio A, Whitmore J, Gilbert MJ: The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial. J Infect Dis (1999) 180(4):1064-1071.
100. Imami N, Hardy GA, Nelson MR, Morris-Jones S, Al-Shahi R, Antonopoulos C, Gazzard B, Gotch FM: Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol (1999) 118(1):78-86.
101. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM: Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nat Med (2001) 7(1):73-79.
102. Okamoto Y, Douek DC, McFarland RD, Koup RA: Effects of exogenous interleukin-7 on human thymus function. Blood (2002) 99(8):2851-2858.
103. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE: IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood (2001) 97(5):1491-1497.
104. Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, Ciccarelli R et al: Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res (1999) 19(1):77-84.
105. Stylianou E, Aukrust P, Nordoy I, Muller F, Froland SS: Enhancement of lymphocyte proliferation induced by interleukin-12 and anti-interleukin-10 in HIV-infected patients during highly active antiretroviral therapy. APMIS (2000) 108(9):601-607.
106. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R: A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS (2002) 16(8):1147-1154.
107. Chappel S: Growth hormone in immune reconstitution. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 20(5):423-431.
108. Mellado M, Llorente M, Rodriguez-Frade JM, Lucas P, Martinez C, Del Real G: HIV-1 envelope protein gp120 triggers a Th2 response in mice that shifts to Th1 in the presence of human growth hormone. Vaccine (1998) 16(11-12):1111-1115.
109. Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N: Growth hormone enhances thymocyte development and induces differentiation into functional peripheral T cells in HAART treated HIV-1+ patients. Ninth Conference on Retroviruses and Opportunistic Infections (2002):Abs 513-M.
110. Napolitano L, Lo J, Gotway M, Mulligan K, Barbour JD, Schmidt D, Halvorsen R, Stoddart C, Schambelan M, McCune JM: Increased thymic mass and circulating naive CD4+ T-cell counts in HIV-1-infected adults treated with growth hormone. Ninth Conference on Retroviruses and Opportunistic Infections (2002):Abs 511-M.
111. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD: Thymosin-α1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol (1999) 21(1):15-26.
112. Beuth J, Schierholz JM, Mayer G: Thymosin α(1) application augments immune response and down-regulated tumor weight and organ colonization in BABL/c-mice. Cancer Lett (2000) 159(1):9-13.
113. Leichtling KD, Serrate SA, Sztein MB: Thymosin α1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol (1990) 12(1):19-29.
114. Garaci E, Rocchi G, Perroni L, D'Agostini C, Soscia F, Grelli S, Mastino A, Favalli C: Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res (1994) 24:23-28.